Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSTAR Lung
2020-003433-37Phase 2Active
- Sponsor
- GSK
- Start
- Nov 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Cobolimab + dostarlimab + docetaxel, Dostarlimab + docetaxel and Docetaxel alone (3 arms). Primary endpoint: Overall survival. Started Nov 2020; status: active.
02
Drugs
cobolimabdostarlimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-003433-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003433-37.